Vladimir Bobkov

Company: Argenx

Job title: Principal Scientist Discovery

Seminars:

Step-Wise Optimization of a Next Generation FcRn Inhibitor Fused to an Albumin-Binder for Improved IgG Clearance 10:00 am

• Development of next-generation FcRn blockers with improved pharmacodynamic effects and reduced frequency of dosing could be highly beneficial for patient quality of life and patient satisfaction • Fc-ABDEG and albumin-binding VHH were combined to develop next-generation FcRn blockers with improved IgG clearance • Step-wise engineering was used to optimize the position and number of…Read more

day: Conference Day One